---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-083250"
form_type: "8-K"
ticker: null
cik: "0001641640"
company_name: "Nabriva Therapeutics plc"
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:14:51.475512+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Nabriva receives Nasdaq delisting notice; trading to suspend Aug 1, 2023

## Summary
- Stockholders' equity deficit of $(4,357,000) as of March 31, 2023 fails $2.5M minimum under Rule 5550(b)(1).
- Nasdaq will suspend trading at open on August 1, 2023; Company will not appeal.
- Ordinary shares may become eligible for Pink Open Market quotation, but no assurances given.

## SEC filing metadata
- accession: 0001104659-23-083250
- form_type: 8-K
- cik: 0001641640
- company_name: Nabriva Therapeutics plc
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/0001104659-23-083250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/tm2321842d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-083250
- JSON: https://secwatch.observer/filing/0001104659-23-083250.json
- Plain text: https://secwatch.observer/filing/0001104659-23-083250.txt

## Key facts
- Listing & Compliance Notices
  Nabriva Therapeutics plc received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: July 21, 2023, Nabriva Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, based on (i) the Company’s continued non-compliance with the Nasdaq Capital Market’s requirement to have a minimum stockholders’ equity of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) (the “Rule”) and (ii) the Company’s confirmation that it did not intend to submit a plan to regain compliance with the Rule, the Company’s ordinary shares, nominal value $0.01 per share (the “Ordinary
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/0001104659-23-083250-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.